This prognostic study (in which a combined correlative analysis of the CALGB 40601 and PAMELA trials was conducted) compares the effectiveness of tumor-infiltrating lymphocytes vs immune-related gene expression signatures in predicting pathologic complete response and event-free survival in patients with early-stage ERBB2/HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.